Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Medical Startup Investors

Last updated: Sep 2023 A list of 50 angel investors and VC funds that invest in Medical startups. We rank investors based on the number of investments they made in Medical companies. This investor list updates every month.

Top 50 Medical Startup Investors

Investor	Medical investments
Innova Memphis	58
New Enterprise Associates	40
OrbiMed	40
Bpifrance	36
ARCH Venture Partners	34
Versant Ventures	32
Connecticut Innovations	32
F-Prime Capital	31
Polaris Partners	31
Qiming Venture Partners	30
Canaan Partners	29
Third Rock Ventures	28
Sofinnova Partners	27
Wisconsin Investment Partners	27
Sequoia Capital China	27
BioAdvance	27
Khosla Ventures	26
Wavemaker 360	25
Enterprise Ireland	25
Novo Holdings	24
Atlas Venture	24
Alumni Ventures	23
Green Park & Golf Ventures	23
Rock Health Capital	23
Lux Capital	23
MB Venture Partners	22
Houston Angel Network	21
StartUp Health	21
Right Side Capital Management	21
BioVenture	21
Parkwalk Advisors	20
High-Tech Grunderfonds	20
UK Innovation & Science Seed Fund	20
Portfolia	19
TEDCO	19
Boehringer Ingelheim Venture Fund	19
General Catalyst	19
Deepbridge Capital	19
M Ventures	19
Domain Associates	19
HealthCap	18
Kurma Partners	18
Scottish Enterprise	18
Sanofi Ventures	18
EQT life science	18
Venrock	18
Novartis Venture Fund	18
Alexandria Venture Investments	17
Pontifax	17
Asset Management Ventures (AMV)	17

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.

Investment focus

Health Care, Medical, Medical Device
Seed, Pre-Seed, Convertible Note
United States, Argentina, United Kingdom

Portfolio highlights

Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.
Isomark Health — Isomark Health is a patented AI-based, real-time and 100% green breath technology that detects and prevents bacterial and viral infections.
Stony Creek Colors — Stony Creek Colors is engaged in the production of bio-based dyes together with farmers, mills, and brands, in partnership with small farmers in the Southeast U.S. Stony Creek Colors was founded by Sarah Bellos in 2012 and is based in Tennessee, United States.

New Enterprise Associates, Inc. is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’slifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.

Investment focus

Software, Health Care, Biotechnology
Series B, Series A, Series C
United States, India, China

Portfolio highlights

Functional Finance — Automated FinOps for Insurance. Unify and automate all of your financial operations, workflows and servicing without replacing your current infrastructure.
Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
Embrace — Stay informed with Embrace's mobile monitoring solutions. Optimize app performance & user experience with our comprehensive platform. Learn more now.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

Star Therapeutics — Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Epigenic Therapeutics — Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
France, United States, Switzerland

Portfolio highlights

Tribun Health — Tribun Health provides a complete digital pathology platform for diagnosis, prognosis and biomarker analysis.
Dattak — Dattak offers cyber insurance solutions based on cybersecurity technologies. Their cybersecurity tools allow us to assess a company's level of cybersecurity without complex questionnaires. They provide their policyholders with a variety of cybersecurity tools to help them prevent and defend against cyberattacks.
Atlendis Labs — Atlendis enables users to lend digital assets to real-world businesses on-chain. Choose your rate and control your portfolio. Start earning real yield today!

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, Canada

Portfolio highlights

TFC Therapeutics — TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer.
Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
Bitterroot Bio — Bitterroot Bio is pioneering the emerging field of cardio-immunology, which investigates the interplay between the immune system and cardiovascular health.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Tentarix Biotherapeutics — Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.
Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
Kate Therapeutics — Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases.

At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.

Investment focus

Health Care, Biotechnology, Software
Series A, Seed, Funding Round
United States, Israel, Canada

Portfolio highlights

Raise Green — Raise Green is the climate tech marketplace for local impact investing licensed with the SEC and FINRA to sell private securities.
OOVA — OOVA is a fertility diagnostic company that spun out from Mount Sinai Hospital in New York City. Using patent pending biochemistry and artificial intelligence, OOVA learns a woman’s fertility profile by accurately measuring key hormones over time through daily urine samples. By monitoring this critical balance of hormones, OOVA can help a woman getpregnant, identify reasons she is having trouble getting pregnant, and even expose reproductive health issues like PCOS.
Driver Technologies — Turn your phone into a dash cam.

F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.

Investment focus

Health Care, Biotechnology, Medical
Series A, Series B, Series C
United States, United Kingdom, China

Portfolio highlights

Simon Data — Simon Data is the Customer Data Platform that enables you to drive marketing results faster with a solution purpose built for growth.
Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.

Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, Singapore, Ireland

Portfolio highlights

Crossbow Therapeutics — Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets.
Candesant Biomedical — Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis. It offers a technology that is based on the principle that alkali metals in contact with water generate energy. The insight was that when the amounts of metal and water are controlled, the result is targeted delivery of energy exactly at the site of the water. Itsdevice is designed to target and inactivate the most active sweat glands.The company was founded in 2016 and is headquartered in San Francisco, California.
Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised. Since our establishment, we have investedin outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 480 fast-growing and innovative companies. Over 180 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange or Shenzhen Stock Exchange, or through M&A or by other means. There are also over 70 portfolio companies that have achieved unicorn status.

Investment focus

Health Care, Medical, Biotechnology
Series B, Series A, Series C
China, United States, Hong Kong

Portfolio highlights

Epigenic Therapeutics — Epigenic Therapeutics is a biotech firm that offers gene editing therapy.
Saints Sages Medical — Saints Sages Medical is engaged in the production and sales of minimally invasive surgical medical devices. They have several energy device products that are widely used in minimally invasive surgery, hepatobiliary surgery, gynecology, urology, thoracic surgery, and other departments. Saints Sages closely monitors clinical needs and develops moreinnovative minimally invasive surgical devices to serve global patients, relying on a professional research and development team and years of the clinical transformation experience.
Atantares — We are a development stage startup enabling the next generation of precision medicine by fusing biochip and AI technologies.

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.

Investment focus

Software, Biotechnology, Health Care
Series A, Series B, Series C
United States, Israel, India

Portfolio highlights

Atmosfy — Atmosfy lets you explore dining through video. Easily browse 10-second, engaging videos from customers who recently dined there.
Savvy — Savvy is a software development company that engages in cybersecurity.
Tomorrow.io — Predict, automate, and solve your biggest weather challenges with Tomorrow.io.

Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
Flare Therapeutics — Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.
CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
AAVantgarde Bio — AAVantgarde Bio is developing gene therapies for inherited retinal disorders.

Wisconsin Investment Partners is an Angel Investment Group in Madison, Wisconsin founded in 2000 with 20 members.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Seed, Series A
United States, Canada, United Kingdom

Portfolio highlights

Flyte — Flyte promotes cellular healing in pelvic floor muscles for lasting results. Flyte is fast, proven, safe, pelvic floor therapy for bladder control.
Sequoir — Sequoir is a financial technology firm providing blockchain trading and custody APIs to power banks, credit unions, fintech, and the Web 3.0.
Nurse Disrupted — A virtual nursing program that retains nurses & improves hospital finances. Live in 4 weeks. Engaged, happier nurses in days.

We help founders build enduring companies.

Investment focus

Health Care, Biotechnology, Artificial Intelligence
Series A, Series B, Series C
China, United States, Australia

Portfolio highlights

Xintu Heterogeneous — Xintu Heterogeneous offers data storage solutions for heterogeneous computing.
Life Wilderness — Life Wilderness reimagines human-computer interaction and is linked to the transportation and travel industries.
FUE Bioscience — FUE Bioscience is a medical robot R&D business that specializes in microsurgery above the head and neck. It continues to develop a product matrix of fully intelligent, high-precision, and anthropomorphic surgical robots based on the platform of macro-micro-controlled humanoid dual-arm robots.

BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United States, Canada

Portfolio highlights

KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.
Senzo — SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST.

Khosla Ventures is a venture capital firm started in 2004 by Vinod Khosla, Co-Founder of Sun Microsystems. The firm provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies.With over $15b assets under management, the firm focuses on a range of areas including consumer, enterprise, education,advertising, financial services, semiconductors, health, big data, agriculture, food, sustainable energy, and robotics. Khosla Ventures is headquartered in Menlo Park, California.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, India, United Kingdom

Portfolio highlights

Alias Technologies — Here at Alias Technologies our goal is to help organizations tackle complex IT goals and initiatives in an ever-changing landscape. Leveraging our Partner relationships and extensive experience we are able to help position our customers for the future.
Arkifi — Arkifi is an artificial intelligence company that develops AI-powered financial analyst tools. Arkifi's framework generates consistent results that avoid fabricating factual details (referred to as "hallucination"), instilling enterprises with an unmatched level of confidence in the outcomes.
Teamshares — One hundred percent close rate on LOIs. Committed capital with no financing contingency. Teamshares is the buyer of choice for your business listing. Request a buyer profile to learn more about us.

Wavemaker Three-Sixty Health is the leading U.S. early-stage (Seed and following on at the Series A) venture capital fund focused 100% on healthcare. Launched in 2018, Wavemaker 360 invested into the most promising healthcare startups in North America, with LPs from every sector of the US healthcare system. We are SEEDING HEALTHCARE'STOMORROW. We invest in healthcare disruptors and entrepreneurs that see how the industry is transforming itself and want to make a big difference.

Investment focus

Health Care, Medical, Medical Device
Seed, Series A, Funding Round
United States, United Kingdom, Canada

Portfolio highlights

32Co — 32Co is a medical technology platform that helps general dentists deliver clear aligner orthodontics to their patients.
Gradient Health — One of the biggest barriers to accelerating AI development is access to large datasets of labeled pathologies.
Essenvia — Rapidly submit eSTAR, EUMDR and IVDR applications, eliminate errors and accelerate approvals with the only regulatory submission platform made for MedTech

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Tailr — Redefining production for the clothing industry.
CergenX — CergenX produces cutting-edge technology for the analysis of baby brain waves that can be used to identify brain injuries early in the newborn period.
Recruitroo — Recruitroo is a international recruitment agency that uses technologies to streamline and improve the international recruitment process for both companies and candidates.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Octave — Octave is a national behavioral health practice that’s creating a new standard for care delivery that’s both high-quality and accessible to more people. With in-person and virtual clinics in California and New York, the company offers personalized care plans that can include individual therapy, couples therapy, and groups, while pioneeringrelationships with payers to make care more affordable through insurance. Grounded in science, Octave enables clients to experience profound change that is as measurable as it is meaningful.
Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.
AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

K36 Therapeutics — K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
AAVantgarde Bio — AAVantgarde Bio is developing gene therapies for inherited retinal disorders.
Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.

Alumni Ventures offers diversified venture portfolios to accredited investors into highly competitive deals that individuals typically do not have access to on their own.

Investment focus

Software, Information Technology, Health Care
Seed, Series A, Series B
United States, United Kingdom, Canada

Portfolio highlights

Alix — Alix is powering wealth across generations. Over the next 2 decades $84 trillion of wealth will be transferred within families. Alix is the platform and service provider to make that transfer totally seamless so those families can focus on what’s most important, each other.
Ascend Elements — Ascend Elements manufactures advanced battery materials using valuable elements reclaimed from discarded lithium-ion batteries. Our patented Hydro-to-Cathode process transforms todays waste into high-value materials for tomorrow's EV batteries a giant step up for sustainability and the entire industry.
TFC Therapeutics — TFC Therapeutics is a biotechnology company developing novel biologics to target and eliminate key drivers of cancer.

Green Park & Golf, built on over 50 years of operational and financial experience, seeks investment opportunities that offer above-market returns for its investors. Led by Clay Heighten, M.D., and Carl Soderstrom, the Firm delivers strategic solutions, financial backing and a reliable network to its portfolio companies. The Dallas-based Firm iscurrently looking for investment opportunities in medical-related start-ups.Dr. Heighten founded MedicalEdge Healthcare Group in 1993, and Mr. Soderstrom started PhyServe Physician Services in 1998 to administer the financial and operational needs of MedicalEdge. Together, the companies managed over 550 providers in five major markets. In 2011, the companies were sold to Texas Health Resources, a $3.8 billion health care system. That’s when Green Park & Golf was born.After earning his MBA at Southern Methodist University, Mr. Garcia joined them full-time in May 2011 to actively pursue new investment opportunities and monitor other investments in their portfolio. He has prior professional experience at FedEx, Bold Ventures, and Lone Star Investment Advisors.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Series B
United States, Israel, Sweden

Portfolio highlights

Worlds — Worlds is completely re-inventing how organizations see and understand their worlds. Through live, AI-powered models, the company’s clients can remotely see, learn and analyze their worlds in ways that were never possible before.
Validic — Meet the only EHR-integrated remote care solution delivering personalized care for clinicians and patients, making personal health data actionable.
Prolocor — Our goal is to develop a more precise method and diagnostic tool for assessing and managing risk in cardiovascular disease.

We invest in remarkable entrepreneurs working at the intersection of healthcare and technology.

Investment focus

Health Care, Software, Medical
Seed, Series A, Series B
United States, Denmark

Portfolio highlights

Oula Health — Oula is a modern maternity clinic combining the best of obstetrics and midwifery care to deliver an evidence-based and personalized pregnancy experience
WellTheory — Our programs support autoimmune lifestyle changes with an actionable and supportive membership experience, no matter where you are in your autoimmune journey.
Ribbon Health — Ribbon Health is building the infrastructure to transform healthcare decisions: with accurate and actionable provider information, including insurance coverage, prices, and performance.

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures our portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Investment focus

Software, Health Care, Biotechnology
Series A, Seed, Series B
United States, Canada, United Kingdom

Portfolio highlights

Ramp — Join thousands of forward-thinking businesses using Ramp to control spend, save time, and automate busywork.
Pivotal Commware — Pivotal Commware was established in 2016 to commercialize a breakthrough in electromagnetic physics, Holographic Beam Forming™ (HBF). Years ago, Pivotal’s founders recognized that wireless demand for data would outgrow the complex coding, multiplexing and modulation schemes that network operators have deployed thus far. Beamforming was theanswer, but existing high cost, size, weight and power-consuming (C-SWaP) solutions were not. That’s why Pivotal assembled a team experienced in advanced commercial antenna and RF circuit design, advanced DARPA technology programs, and, uniquely, active/nonlinear metamaterials. Beyond technology, Pivotal also offers the depth and breadth of skills to develop integrated, end-to-end solutions.
Mendaera — Mendaera enables all healthcare providers to perform precise and consistent point-of-care interventions. Their platform combines real-time imaging, robotics, and artificial intelligence to aid physicians in image acquisition and interpretation.

MB Venture Partners in Memphis, TN provides venture capital for life sciences: medical device, biotechnology companies, products for musculoskeletal diseases

Investment focus

Health Care, Medical, Medical Device
Seed, Series B, Series C
United States, Israel

Portfolio highlights

Lineus Medical — Lineus Medical is a medical device company focused on reducing IV complications for patients and providers all over the world.
SweetBio — SweetBio is a Memphis, Tennessee based medical device company specializing in bioengineering honey-incorporated materials for wound care.
Cast21 — The future of orthopedic technology has arrived. Cast21 braces are designed for your active lifestyle.

The Houston Angel Network (HAN) is a nonprofit organization dedicated to developing the innovation ecosystem in Houston, Texas by supporting founders and startups with financial resources and mentorship.

Investment focus

Health Care, Software, Information Technology
Seed, Funding Round, Series A
United States, Canada, United Kingdom

Portfolio highlights

Amplified Sciences — Amplified Sciences is a molecular diagnostics company unlike other diagnostics companies due to their ultra-sensitive molecular sensing technology with composition of matter IP exclusively licensed from Purdue University. The technology is disease state agnostic, can detect to the single molecule level, scales easily to point of care, and providesa very favorable cost structure for their platform of reagents. The first application – early detection of pancreatic cancer - is an assay that will quickly prove the investment thesis due to large unmet medical need and a favorable reimbursement path. The team has delivered a working prototype and published proof of concept data.
CaseCTRL — Schedule surgeries with ease using AI-powered surgical scheduling. Fewer canceled cases, conflicts, and misorders. More surgery and time for patients!
Materna Medical — Materna Medical empowers women to protect and restore their pelvic health.

Organizing and investing in a global army of entrepreneurs committed to achieving health moonshots

Investment focus

Health Care, Wellness, Medical
Seed, Funding Round, Pre-Seed
United States, Canada, United Kingdom

Portfolio highlights

AvoMD — AvoMD is reimagining clinical decision support with interactive point-of-care software, available standalone and via EHR integrations, and seamless content building tools.
Pear Suite — Pear Suite enables anyone—community health workers, other healthcare staff, and volunteers—to assess and address the social drivers of health for older adults in a scalable, cost-effective, and person-centered way.
Medwise.ai — Medwise.ai is the Google for doctors.

Right Side Capital Management is a venture capital firm that helps startups build their company. It invests exclusively in the pre-seed round of technology startups and makes 75-100 investment per year. The firms prefers to invest in diversified technology sectors such as the internet and cloud companies.RSCM was established in 2010 and is basedin San Francisco, California.

Investment focus

Software, SaaS, Health Care
Seed, Pre-Seed, Convertible Note
United States, Canada, United Kingdom

Portfolio highlights

OFFSITE — OFFSITE provides cloud computing and data center solutions.
Offsite — Offsite operates a platform that provides retreat planning for remote and hybrid teams. The company helps in the planning, management, and follow-up of team retreats, client-facing events, and other transformational, in-person experiences.
Aiden — Reduce risk, enhance compliance, and simplify IT with modern, intelligent software packaging and deployment using Artificial Intelligence.

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.

Investment focus

Health Care, Medical, Biotechnology
Series A, Series B, Series C
China, United States, Taiwan

Portfolio highlights

Jiamuyao Medical — Jiamuyao Medical specialized in developing an energy platform for the comprehensive treatment of complex intravascular lesions.
Xiguang Bio — Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions.
Panomic Biomedical Technology — Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolitepreprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

RoboK — A Cambridge University spin-out building cost-effective 3D sensing software technology
PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.
Wayland Additive — Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
sewts — Founded in 2019 and based in Munich, sewts GmbH provides cutting-edge perception software, pushing the boundaries of robotics in processing of easily deformable materials. sewts has developed and demonstrated a unique technology that uses high-precision finite element method (FEM) simulations to efficiently train machine learning algorithms. Theintelligent software solution enables countless applications in industrial automation like the handling of textiles in industrial laundries or the manufacturing of garment. sewts is backed by APEX Ventures, Bayern Kapital, High-Tech Gründerfonds, UnternehmerTUM Initiative for Industrial Innovators and a couple of highly experienced business angels.
Yond — Yond is Prepared to scale your business with our Gym Operating System.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

CHAIN Biotechnology — CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology.
NK:IO — NK:IO is a biotech company that develops novel approaches to natural killer cell-mediated immunotherapy. The company develops both cell therapy and small molecule therapeutics primarily targeting cancer.
Resurrect Bio — Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.

Investing Funds Designed for Women Backing Innovative Companies We Want in the World - For Returns and Impact

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United States, Canada, Argentina

Portfolio highlights

Attn: Grace — Attn: Grace is a sustainable wellness brand designed for women. Starting with bladder leakage, they're creating thoughtful, more sustainable solutions for life’s inconvenient truths, one challenge at a time.
Prime Roots — Prime Roots is on a mission to provide a better cut of meat for every type of eater. Rooted in koji, Prime Roots is able to replicate the taste and texture of meat without any of the environmental costs of animal proteins.
Carbice Corporation — Carbice is the first no-compromise thermal interface material. It achieves all the advantages of both solid and liquid thermal interface materials without any of the pitfalls.

TEDCO was created by the Maryland State Legislature in 1998 to facilitate the transfer and commercialization of technology from Maryland’s research universities and federal labs into the marketplace and to assist in the creation and growth of technology-based businesses in all regions of the State. TEDCO is an independent organization thatstrives to be Maryland’s lead source for entrepreneurial business assistance and seed funding for the development of startup companies in Maryland’s innovation economy. In Maryland and beyond, TEDCO is a resource of mentoring, funding and networking for entrepreneurs and start-ups that need guidance as they bring innovative concepts to market. TEDCO is more than an early stage funding resource. It is the hub of Maryland’s entrepreneurial network where startups find mentors, organizational assistance, facilities for daily operations, and a roadmap for success.

Investment focus

Software, Health Care, Biotechnology
Seed, Pre-Seed, Series A
United States

Portfolio highlights

N5 Sensors — Sensors and solutions for protecting lives and infrastructure from environmental hazards.
Fem Equity — Fem Equity is a work platform that develops real-time solutions for women and underrepresented professionals experiencing salary or professional inequalities.
Hopr — Hopr recognizes the increasing relevance of cybersecurity in today's global digital society. Hopr objective is to assist organizations in protecting their digital operations and data by rethinking old challenges and then developing innovative cybersecurity solutions to tackle them.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

Investing in powerful, positive change that endures

Investment focus

Software, Health Care, Internet
Series A, Series B, Seed
United States, United Kingdom, India

Portfolio highlights

Modular — Modular is the next-generation AI developer platform unifying the development and deployment of AI for the world.
Ramp — Join thousands of forward-thinking businesses using Ramp to control spend, save time, and automate busywork.
Georgiamune — Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .
Circada — Innovative Circadian lighting reconnects the body clock with nature
FluoretiQ — FluoretiQ is a medical device company designing simple and effective bacterial detection systems for rapid diagnosis of infection. They developing a new solution that combines proprietary nanomaterials and optical sensing technologies to enable the identification of harmful bacteria in minutes. The company nanotechnology utilizes receptor-mediatedsensing and Quantum-enhanced optics for the rapid identification of bacterial infection.FluoretiQ developed NANOPLEXa rapid diagnostic platform that identifies and enumerates bacterial pathogens in less than 15 minutes. The NANOPLEXa ensures that patients receive the most effective antibiotic treatment from the start. Their products easy-to-use, providing clinicians with the data to support accurate-same-day diagnosis and more appropriate antibiotic selection.FlouretiQ was founded in 2017 and is headquartered in Bristol, United Kingdom.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
Celestial AI — We develop audacious AI computing platforms that elevate performance, energy and economic efficiencies, enabling our customers to rapidly deploy innovations in their AI applications.

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.Domainâ€™s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices,while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Canada, Estonia

Portfolio highlights

Epic Sciences — Epic Sciences develops clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer.
Fractyl Health — Our vision is to develop transformative therapies that have the potential to prevent and eliminate metabolic diseases. We are a mission-driven team of innovators, singularly
Antios Therapeutics — This is an example page. It's different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this: Hi there! I'm a bike messenger

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Hemab — Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Medical
Series A, Seed, Series B
France, Spain, Switzerland

Portfolio highlights

Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
Kiro — Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology.
Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

Rapscallion Soda — Award Winning, Fresh Fruit, Low Calorie Soft Drinks, Handmade in Scotland. Fresh batches made weekly. Free UK Mainland Delivery. International Shipping. Ginga Ninja | Burnt Lemon | Dry Lime | Scottish Rhubarb Soda | Scottish Strawberry Soda | Cranachan Soda | Blueberry Soda Love soda. Hate hangovers. Drink local.
Pneumagen — Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology.
Heero Technologies — Heero Technologies, the leading independent energy platform for making net zero homes a reality

Sanofi Ventures invests in top tier biotherapeutic and digital health entrepreneurs who focus on helping patients and transforming the healthcare system.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Israel, Denmark

Portfolio highlights

Abcuro — Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
Tisento Therapeutics — Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.
Therini Bio — Therini Bio is developing novel therapeutics based insights into the role of fibrin in driving chronic innate immune activation.

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.

Building Companies that Shape the Future

Investment focus

Health Care, Biotechnology, Software
Series B, Series A, Series C
United States, Canada, China

Portfolio highlights

Tisento Therapeutics — Tisento Therapeutics is a MA-based developer of novel medicines to treat diseases with significant unmet medical needs.
SQLite Cloud — SQLite Cloud is a cloud-based service that offers an easy-to-use and highly scalable platform for managing SQLite databases in the cloud. Our product provides a secure and reliable way to store, manage, and share SQLite databases without requiring any server setup or maintenance. With our service, customers can easily create new databases, importexisting databases, and collaborate with others on their projects. Our product also offers various features such as automated backups, point-in-time recovery, and real-time replication, which ensures high availability and data durability. Our goal is to make database management as easy and hassle-free as possible for our customers.
Aledade — Aledade is a primary care physician platform to provide everything the doctors to create and run an Accountable Care Organization. Aledade partners with independent, primary care physicians to provide everything the doctors need to create and run an Accountable Care Organization (ACO) from business and practice transformation services to upfrontcapital and a cutting-edge technology platform. The company customized solutions and continuous, on-the-ground support of our physician partners will help doctors in all types of communities across America preserve their autonomy, deliver better care to their patients, reduce overall costs, and keep independent physician practices flourishing.Adelade was founded in 2014 and is headquartered in Bethesda, Maryland, United States.

Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, France, Canada

Portfolio highlights

Bitterroot Bio — Bitterroot Bio is pioneering the emerging field of cardio-immunology, which investigates the interplay between the immune system and cardiovascular health.
Ten63 Therapeutics — Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Orbital Therapeutics — Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible.

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Israel, France

Portfolio highlights

Precirix — Developing radio-immunotherapeutic drugs for cancer patients.
ARMGO,Pharma,Inc. — ARMGO Pharma, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. It offers rycals, which are calcium release channel stabilizers that act on ryanodine receptor/calcium release channel, a therapeutic target located on thesarcoplasmic/endoplasmic reticulum of the cell for treating chronic heart failure, cardiac arrythmias, and muscle disorders, as well as cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. The company was incorporated in 2004 and is based in Tarrytown, New York with an additional office in New York, New York.
Anaveon — Anaveon is a biopharmaceutical company that transforms engineered cytokines into novel life-saving treatments. The first program going into clinical trials is a selective IL-2 receptor agonist.

AMV is the leading early-stage venture capital firm investing in digital health, technology and life sciences. It has assembled the leading early-stage

Investment focus

Health Care, Biotechnology, Software
Series A, Seed, Series B
United States, Cyprus, Ireland

Portfolio highlights

Autonomize AI — Autonomize AI is a human-centric AI platform that learns from multi-structured clinical and biomedical data and pairs it with human context to aid decision-making and data discovery. They extract contextual information from multi-structured healthcare data, enrich with human know-how, and aid decision-making and data discovery.
SubjectWell — SubjectWell is the risk-free clinical trials marketplace for patient recruitment
Carta Healthcare — Our industry-leading, AI-driven technology converts both structured and unstructured healthcare data into a high-quality, reliable, standardized dataset that can be used across your organization.

Investors by industry